The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity

Romina Fiorotto, Ambra Villani, Antonis Kourtidis, Roberto Scirpo, Mariangela Amenduni, Peter J. Geibel, Massimiliano Cadamuro, Carlo Spirli, Panagiotis Z Anastasiadis, Mario Strazzabosco

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In the liver, the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) regulates bile secretion and other functions at the apical membrane of biliary epithelial cells (i.e., cholangiocytes). CF-related liver disease is a major cause of death in patients with CF. CFTR dysfunction affects innate immune pathways, generating a para-inflammatory status in the liver and other epithelia. This study investigates the mechanisms linking CFTR to toll-like receptor 4 activity. We found that CFTR is associated with a multiprotein complex at the apical membrane of normal mouse cholangiocytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity. In CFTR-defective cholangiocytes, Src tyrosine kinase self-activates and phosphorylates toll-like receptor 4, resulting in activation of nuclear factor kappa-light-chain-enhancer of activated B cells and increased proinflammatory cytokine production in response to endotoxins. This Src/nuclear factor kappa-light-chain-enhancer of activated B cells-dependent inflammatory process attracts inflammatory cells but also generates changes in the apical junctional complex and loss of epithelial barrier function. Inhibition of Src decreased the inflammatory response of CF cholangiocytes to lipopolysaccharide, rescued the junctional defect in vitro, and significantly attenuated endotoxin-induced biliary damage and inflammation in vivo (Cftr knockout mice). Conclusion: These findings reveal a novel function of CFTR as a regulator of toll-like receptor 4 responses and cell polarity in biliary epithelial cells; this mechanism is pathogenetic, as shown by the protective effects of Src inhibition in vivo, and may be a novel therapeutic target in CF-related liver disease and other inflammatory cholangiopathies. (Hepatology 2016;64:2118-2134).

Original languageEnglish (US)
Pages (from-to)2118-2134
Number of pages17
JournalHepatology
Volume64
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
src-Family Kinases
Cystic Fibrosis
Toll-Like Receptor 4
Permeability
Inflammation
Endotoxins
Liver Diseases
B-Lymphocytes
Avian Sarcoma
Epithelial Cells
Light
Multiprotein Complexes
Cell Polarity
Membranes
Liver
Gastroenterology
Oncogenes
Knockout Mice
Bile

ASJC Scopus subject areas

  • Hepatology

Cite this

Fiorotto, R., Villani, A., Kourtidis, A., Scirpo, R., Amenduni, M., Geibel, P. J., ... Strazzabosco, M. (2016). The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology, 64(6), 2118-2134. https://doi.org/10.1002/hep.28817

The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. / Fiorotto, Romina; Villani, Ambra; Kourtidis, Antonis; Scirpo, Roberto; Amenduni, Mariangela; Geibel, Peter J.; Cadamuro, Massimiliano; Spirli, Carlo; Anastasiadis, Panagiotis Z; Strazzabosco, Mario.

In: Hepatology, Vol. 64, No. 6, 01.12.2016, p. 2118-2134.

Research output: Contribution to journalArticle

Fiorotto, R, Villani, A, Kourtidis, A, Scirpo, R, Amenduni, M, Geibel, PJ, Cadamuro, M, Spirli, C, Anastasiadis, PZ & Strazzabosco, M 2016, 'The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity', Hepatology, vol. 64, no. 6, pp. 2118-2134. https://doi.org/10.1002/hep.28817
Fiorotto, Romina ; Villani, Ambra ; Kourtidis, Antonis ; Scirpo, Roberto ; Amenduni, Mariangela ; Geibel, Peter J. ; Cadamuro, Massimiliano ; Spirli, Carlo ; Anastasiadis, Panagiotis Z ; Strazzabosco, Mario. / The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. In: Hepatology. 2016 ; Vol. 64, No. 6. pp. 2118-2134.
@article{238566cce8c0475a8b8e99a0b1cd00b2,
title = "The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity",
abstract = "In the liver, the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) regulates bile secretion and other functions at the apical membrane of biliary epithelial cells (i.e., cholangiocytes). CF-related liver disease is a major cause of death in patients with CF. CFTR dysfunction affects innate immune pathways, generating a para-inflammatory status in the liver and other epithelia. This study investigates the mechanisms linking CFTR to toll-like receptor 4 activity. We found that CFTR is associated with a multiprotein complex at the apical membrane of normal mouse cholangiocytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity. In CFTR-defective cholangiocytes, Src tyrosine kinase self-activates and phosphorylates toll-like receptor 4, resulting in activation of nuclear factor kappa-light-chain-enhancer of activated B cells and increased proinflammatory cytokine production in response to endotoxins. This Src/nuclear factor kappa-light-chain-enhancer of activated B cells-dependent inflammatory process attracts inflammatory cells but also generates changes in the apical junctional complex and loss of epithelial barrier function. Inhibition of Src decreased the inflammatory response of CF cholangiocytes to lipopolysaccharide, rescued the junctional defect in vitro, and significantly attenuated endotoxin-induced biliary damage and inflammation in vivo (Cftr knockout mice). Conclusion: These findings reveal a novel function of CFTR as a regulator of toll-like receptor 4 responses and cell polarity in biliary epithelial cells; this mechanism is pathogenetic, as shown by the protective effects of Src inhibition in vivo, and may be a novel therapeutic target in CF-related liver disease and other inflammatory cholangiopathies. (Hepatology 2016;64:2118-2134).",
author = "Romina Fiorotto and Ambra Villani and Antonis Kourtidis and Roberto Scirpo and Mariangela Amenduni and Geibel, {Peter J.} and Massimiliano Cadamuro and Carlo Spirli and Anastasiadis, {Panagiotis Z} and Mario Strazzabosco",
year = "2016",
month = "12",
day = "1",
doi = "10.1002/hep.28817",
language = "English (US)",
volume = "64",
pages = "2118--2134",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity

AU - Fiorotto, Romina

AU - Villani, Ambra

AU - Kourtidis, Antonis

AU - Scirpo, Roberto

AU - Amenduni, Mariangela

AU - Geibel, Peter J.

AU - Cadamuro, Massimiliano

AU - Spirli, Carlo

AU - Anastasiadis, Panagiotis Z

AU - Strazzabosco, Mario

PY - 2016/12/1

Y1 - 2016/12/1

N2 - In the liver, the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) regulates bile secretion and other functions at the apical membrane of biliary epithelial cells (i.e., cholangiocytes). CF-related liver disease is a major cause of death in patients with CF. CFTR dysfunction affects innate immune pathways, generating a para-inflammatory status in the liver and other epithelia. This study investigates the mechanisms linking CFTR to toll-like receptor 4 activity. We found that CFTR is associated with a multiprotein complex at the apical membrane of normal mouse cholangiocytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity. In CFTR-defective cholangiocytes, Src tyrosine kinase self-activates and phosphorylates toll-like receptor 4, resulting in activation of nuclear factor kappa-light-chain-enhancer of activated B cells and increased proinflammatory cytokine production in response to endotoxins. This Src/nuclear factor kappa-light-chain-enhancer of activated B cells-dependent inflammatory process attracts inflammatory cells but also generates changes in the apical junctional complex and loss of epithelial barrier function. Inhibition of Src decreased the inflammatory response of CF cholangiocytes to lipopolysaccharide, rescued the junctional defect in vitro, and significantly attenuated endotoxin-induced biliary damage and inflammation in vivo (Cftr knockout mice). Conclusion: These findings reveal a novel function of CFTR as a regulator of toll-like receptor 4 responses and cell polarity in biliary epithelial cells; this mechanism is pathogenetic, as shown by the protective effects of Src inhibition in vivo, and may be a novel therapeutic target in CF-related liver disease and other inflammatory cholangiopathies. (Hepatology 2016;64:2118-2134).

AB - In the liver, the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) regulates bile secretion and other functions at the apical membrane of biliary epithelial cells (i.e., cholangiocytes). CF-related liver disease is a major cause of death in patients with CF. CFTR dysfunction affects innate immune pathways, generating a para-inflammatory status in the liver and other epithelia. This study investigates the mechanisms linking CFTR to toll-like receptor 4 activity. We found that CFTR is associated with a multiprotein complex at the apical membrane of normal mouse cholangiocytes, with proteins that negatively control Rous sarcoma oncogene cellular homolog (Src) activity. In CFTR-defective cholangiocytes, Src tyrosine kinase self-activates and phosphorylates toll-like receptor 4, resulting in activation of nuclear factor kappa-light-chain-enhancer of activated B cells and increased proinflammatory cytokine production in response to endotoxins. This Src/nuclear factor kappa-light-chain-enhancer of activated B cells-dependent inflammatory process attracts inflammatory cells but also generates changes in the apical junctional complex and loss of epithelial barrier function. Inhibition of Src decreased the inflammatory response of CF cholangiocytes to lipopolysaccharide, rescued the junctional defect in vitro, and significantly attenuated endotoxin-induced biliary damage and inflammation in vivo (Cftr knockout mice). Conclusion: These findings reveal a novel function of CFTR as a regulator of toll-like receptor 4 responses and cell polarity in biliary epithelial cells; this mechanism is pathogenetic, as shown by the protective effects of Src inhibition in vivo, and may be a novel therapeutic target in CF-related liver disease and other inflammatory cholangiopathies. (Hepatology 2016;64:2118-2134).

UR - http://www.scopus.com/inward/record.url?scp=84995584226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995584226&partnerID=8YFLogxK

U2 - 10.1002/hep.28817

DO - 10.1002/hep.28817

M3 - Article

C2 - 27629435

AN - SCOPUS:84995584226

VL - 64

SP - 2118

EP - 2134

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -